CClinicalTrials.gg
RecruitingNCT076265930 TO 100Updated Jun 4, 2026

The Extraordinary Endurance of the Human Species

An interventional study of Intensive training in Healthy Volunteers, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 25 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
25 Years to 50 Years
Sex
All
01

Study summary

We hypothesize, based on field and scientific data, that setting a very ambitious goal such as completing a mountain ultra-marathon could motivate sedentary and inactive individuals not only to begin training but also to follow a progressive yet extremely ambitious program that has not yet been studied comprehensively. Indeed, the effects of intense and prolonged endurance training (18 months) on the health and performance of completely sedentary individuals have never been investigated exhaustively.

02

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Ultra-endurance
  • Sedentary
  • Healthy volunteers
03

In context

Sedentary Behavior

332 studies on the registry are indexed under Sedentary Behavior; 156 are open to participants now.

This study's planned enrollment of 40 is below the median of 70 across 287 interventional studies indexed under Sedentary Behavior.

Browse Sedentary Behavior studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 578 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Affiliation to social security.
  • Informed consent signed.
  • Male or female, aged 25-50.
  • Sedentary (>6h/day sitting) and inactive (no regular training), assessed by GPAQ questionnaire.

Exclusion criteria

Exclusion Criteria:

  • Chronic joint or cardiac diseases.
  • Neurological disorders.
  • Legal protection status.
  • Moderate to severe depression (BDI-13 > 7) or use of antidepressants/anxiolytics.
  • Use of banned substances.
  • Excessive alcohol or caffeine consumption.
  • Pregnancy.
  • Inability to understand or consent.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Endurance training

    From March 1, 2026 to August 2027, participants will follow individualized coaching: starting at 5-6 hours per week and progressing to 7-10 hours (rarely 15 hours) per week before mountain ultra marathon

    Behavioral: Intensive training

Interventions

  • BehavioralIntensive training

    participants will follow individualized coaching: starting at 5-6 hours per week and progressing to 7-10 hours (rarely 15 hours) per week before mountain ultra marathon

06

What researchers measure

Primary outcomes

  1. Transition from sedentary lifestyle to regular activity and completion of a 100 km ultra-trail

    Percentage of participants who (i) become sufficiently active to be ready to start the Courmayeur-Champex-Chamonix (CCC) 100 km ultra-trail of the Ultra Trail du Mont-Blanc, and (ii) complete the 100 km CCC race.

    Time frame: up to 18 months

Secondary outcomes

  1. Safety and tolerance of progressive endurance training

    Rate of injuries or adverse events reported weekly, and dropout rate over the 18-month training period.

    Time frame: Weekly reporting during the 18-month intervention period

  2. Feasibility and adherence to the endurance training program

    Proportion of scheduled training sessions completed by participants and the percentage of participants finishing the 100 km CCC ultra-trail among those who started the race.

    Time frame: up to 18 months

07

Study locations

1 of 1 sites recruiting
  • CHU de Saint-Etienne
    Saint-Etienne, 42055, France
    • Léonard FEASSON, MD Phd · Contact · leonard.feasson@chu-st-etienne.fr · (0)4 77 82 83 00
    • David HUPIN, MD · Sub investigator
    • Clément FOSCHIA, MD · Sub investigator
    • Philippe BOIRON, MD · Sub investigator
    • Renan PLANCHER, MD · Sub investigator
    • Rémi VASSEUR, MD · Sub investigator
    • Laurent GERGELE, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — we are not decided for the moment

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07626593
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Feb 3, 2026
Primary completion
Sep 28, 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Leonard FEASSON, MD Phd
Contact
leonard.feasson@chu-st-etienne.fr
(0)4 77 82 83 00 ext. +33
Céline LECLERCQ-TRAUTVETTER, CDP
Contact
Celine.LECLERCQ-TRAUTVETTER@chu-st-etienne.fr
04 77 82 94 27 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion